From the category archives:

2008

Impact of the recall period on measuring health utilities for acute events

by Nick on December 28, 2008

Impact of the recall period on measuring health utilities for acute events

by Nick on December 1, 2008

Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States

by Nick on December 1, 2008

Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis

by Nick on September 1, 2008

Health state utility values: A description of their development and application for rheumatic diseases

by Nick on July 1, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 28, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 1, 2008

Biologic Drugs for Rheumatoid Arthritis in the Medicare Program

by Nick on April 1, 2008

The Validity and Responsiveness of Generic Utility Measures in Rheumatoid Arthritis: A Review

by Nick on April 1, 2008

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

by Nick on February 1, 2008